AstraZeneca Licenses Global Rights To Oncology Compound From China’s Hutchison
This article was originally published in PharmAsia News
Executive Summary
AstraZeneca pays $20 million up front to license Hutchison’s Phase I-ready compound in another sign that the U.K. pharma has its eyes set firmly on China.